Fig. 3
From: Loss of the candidate tumor suppressor ZEB1 (TCF8, ZFHX1A) in Sézary syndrome
A Sequence electropherograms showing the germline heterozygous c.2519 A > C (Q840P) (left) and c.696 G > A (T232T) (right) rare variations identified in the normal DNA of P55 (N) which become hemizygous following the loss of the wild-type allele in the tumor sample (T). B, C Sequence electropherograms of DNA patients displaying rare c.69 T > C, Y23Y, and the newly identified c.2557 G > A, V853I; c.3290 G > A, R1097K; c.*25 T > C germline variants. The percentage of neoplastic CD4 + cells are indicated for each patient as well as the ZEB1 status. D Comparison of survival time (months) between SS patients carrying no change or loss of copy number (n = 34, blue line) vs. biallelic deletion (n = 7, red line) of ZEB1 gene. Patients with truncating (R301*, L689*) or loss-of-function mutations (Q840P) associated with loss were included in the biallelic deleted group. Forty-one out of 43 patients were used for this analysis because one was lost at follow-up and the other had an evolution of SS after a long stable MF disease
